A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

Clinical trial NCT07266428 · RECRUITING

Trial details

NCT number: NCT07266428
Sponsor: Ottimo Pharma Limited
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumors

Start date: 2025-12-17
Primary completion: 2028-12-01
Enrollment: 170

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.